以组蛋白去乙酰化酶为靶点的抗肿瘤研究

摘要/Abstract

摘要： 细胞核内组蛋白乙酰化与去乙酰化失衡可诱发肿瘤。组蛋白去乙酰化酶(HDAC)作用于组蛋白，使其去乙酰化，维系组蛋白乙酰化与去乙酰化的平衡状态，与癌相关基因转录表达、细胞增殖分化及细胞凋亡等过程密切相关。HDAC抑制剂目前是国内外研究的热点，已有十多种HDAC抑制剂用于治疗血液肿瘤和恶性实体瘤，表现出明显的抗肿瘤活性。

关键词: 肿瘤, 组蛋白去乙酰化酶, 组蛋白去乙酰化酶抑制剂

Abstract: The disequilibrium of histone acetylation and deacetylation may cause tumor. Histone deacetylases (HDACs) maintain the equilibrium between histone acetylation and deacetylation by catalyzing the deacetylation of histone. They are related to many regulation processes containing transcription of oncogene, cell proliferation and differentiation, apoptosis and so on. HDACs inhibitors have become the hot field of researches, more than ten different HDACs inhibitors are testing for the treatment of both hematological and solid malignancies and show obvious antitumor activity.

Key words: Neoplasms, Histone deacetylase, Histone deacetylase inhibitor

李楠, 蒋大明, 刘双萍. 以组蛋白去乙酰化酶为靶点的抗肿瘤研究[J]. 国际肿瘤学杂志, 2016, 43(2): 116-.

LI Nan, JIANG Da-Ming, LIU Shuang-Ping. Research on histone deacetylase as a target for anticancer therapy[J]. Journal of International Oncology, 2016, 43(2): 116-.

参考文献

［1］ Yang R, Wu Y, Wang M, et al. HDAC9 promotes glioblastoma growth via TAZmediated EGFR pathway activation［J］. Oncotarget, 2015, 6(10): 76447656. ［2］ Damaskos C, Karatzas T, Nikolidakis L, et al. Histone deacetylase (HDAC) inhibitors: current evidence for therapeutic activities in pancreatic cancer［J］. Anticancer Res, 2015, 35(6): 31293135. ［3］ Koeneke E, Witt O, Oehme I. HDAC family members intertwined in the regulation of autophagy: a druggable vulnerability in aggressive tumor entities［J］. Cells, 2015, 4(2): 135168. DOI:10.3390/cells4020135. ［4］ Herr MJ, Longhurst CM, Baker B, et al. Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activity［J］. Biochem Biophys Res Commun, 2014, 447(4): 616620. DOI:10.1016/j.bbrc.2014.04.046. ［5］ Ding G, Liu HD, Huang Q, et al. HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity［J］. FEBS Lett, 2013, 587(7): 880886. DOI:10.1016/j.febslet.2013.02.001. ［6］ Seo J, Min SK, Park HR, et al. Expression of histone deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in invasive ductal carcinomas of the breast［J］. J Breast Cancer, 2014, 17(4): 323331. DOI:10.4048/jbc.2014.17.4.323. ［7］ Chen MC, Chen CH, Wang JC, et al. The HDAC inhibitor, MPT0E028, enhances erlotinibinduced cell death in EGFRTKIresistant NSCLC cells［J］. Cell Death Dis, 2013, 4: e810. DOI:10.1038/cddis.2013.330. ［8］ Liu J, Edagawa M, Goshima H, et al. Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic antiDR5 antibody through ER stress in human colon cancer cells［J］. Biochem Biophys Res Commun, 2014, 445(2): 320326. DOI:10.1016/j.bbrc.2014.01.184. ［9］ Zhao B, He T. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl2 and P21 in pancreatic cancer［J］. Oncol Rep, 2015, 33(1): 304310. DOI:10.3892/or.2014.3595. ［10］ Jin JS, Tsao TY, Sun PC, et al. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin［J］. Pathol Oncol Res, 2012, 18(3): 713720. DOI:10.1007/s1225301294997. ［11］ Noh EJ, Lim DS, Jeong G, et al. An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcriptiondependent manner［J］. Biochem Biophys Res Commun, 2009, 378(3): 326331. DOI:10.1016/j.bbrc.2008.11.057. ［12］ Yang B, Yu D, Liu J, et al. Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo［J］. Tumour Biol, 2015, 36(7): 50515061. DOI:10.1007/s1327701531561. ［13］ Bae HJ, Jung KH, Eun JW, et al. MicroRNA221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer［J］. J Hepatol, 2015, 63(2): 408419. DOI:10.1016/j.jhep.2015.03.019. ［14］ Qiao Z, Ren S, Li W, et al. Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells［J］. Biochem Biophys Res Commun, 2013, 434(1): 95101. DOI:10.1016/j.bbrc.2013.03.059. ［15］ Dong M, Ning ZQ, Xing PY, et al. Phase Ⅰ study of chidamide (CS055/HBI8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas［J］. Cancer Chemother Pharmacol, 2012, 69(6): 14131422. DOI:10.1007/s0028001218475. ［16］ Mahalingam D, Mita M, Sarantopoulos J, et al. Combined autophagy and HDAC inhibition: a phase Ⅰ safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors［J］. Autophagy, 2014, 10(8): 14031414. DOI:10.4161/auto.29231. ［17］ Prince HM, Dickinson M. Romidepsin for cutaneous Tcell lymphoma［J］. Clin Cancer Res, 2012, 18(13): 35093515. DOI:10.1158/10780432.CCR113144.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.